Resmed Inc
RMD- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000943819
In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 4 sales; 894 institutions reported holding it in 13F filings for Q2 2026, worth $19.4B in total; Giverny Capital is the only superinvestor holding it.
Other share classesRSMDF
Key figures
- Market capClose on Nov 11, 2026
- $33.6B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.57M in total
- 4
- 13F holdersQ2 2026, −45 vs. previous quarter
- 894
- 13F valueReported value at the end of Q2 2026
- $19.4B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $5.65B
- +9.9% year over year
- Net income, FY2026
- $1.52B
- +8.8% year over year
- Free cash flow, FY2026
- $1.65B
- −0.7% year over year
- Revenue, Q1 FY2027
- $1.41B
- +5.9% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.5M
- Shares sold short
- Change
- −1.45M
- −12.2% vs. previous
- Days to cover
- 7.05
- At average daily volume
Superinvestors holding RMD, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Resmed Inc on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Resmed Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2026 (view filing)3:39 PM ET | Oct 23 | 3 days | Rider Michael JGlobal General Counsel | SSaleResMed Common Stock | −400 | $255.00 | −$102.0K | −3.1%12.3K after | 10b5-1 |
| Oct 8, 2026 (view filing)5:31 PM ET | Oct 7 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $226.33 | −$1.13M | −1.0%479.8K after | 10b5-1 |
| Sep 10, 2026 (view filing)6:40 AM ET | Sep 8 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $222.44 | −$1.11M | −1.1%466.3K after | From original |
| Sep 4, 2026 (view filing)6:30 AM ET | Sep 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −970 | $234.73 | −$227.7K | −1.8%51.8K after | 10b5-1 |
| Aug 11, 2026 (view filing)6:30 AM ET | Aug 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $205.69 | −$1.03M | −1.1%466.3K after | 10b5-1 |
| Aug 6, 2026 (view filing)2:29 PM ET | Aug 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −8.00K | $225.00 | −$1.80M | −13.2%52.8K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:40 AM ET | Jul 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $218.55 | −$1.09M | −1.1%466.2K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $193.96 | −$968.1K | −1.1%466.3K after | 10b5-1 |
| May 11, 2026 (view filing) | May 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $207.82 | −$1.04M | −1.1%466.2K after | 10b5-1 |
| Apr 9, 2026 (view filing) | Apr 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $225.50 | −$1.13M | −1.1%466.2K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 894 holdersThe largest institutional positions in Resmed Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | $2.40B | 0.04% | +223,171+1.8% | Added |
| Vanguard Capital Management LLC | 9,474,129 | $1.85B | 0.04% | +7,713+0.1% | Added |
| Vanguard Portfolio Management LLC | 7,913,661 | $1.54B | 0.07% | +49,739+0.6% | Added |
| State Street Corp | 6,680,735 | $1.30B | 0.04% | +37,567+0.6% | Added |
| Geode Capital Management, LLC | 4,352,320 | $845.2M | 0.05% | −5530.0% | Reduced |
| Bank of New York Mellon Corp | 4,197,610 | $818.0M | 0.13% | −727,776−14.8% | Reduced |
| First Trust Advisors LP | 2,278,696 | $444.1M | 0.26% | +740,871+48.2% | Added |
| Invesco Ltd. | 2,063,578 | $402.1M | 0.03% | +106,964+5.5% | Added |
| Morgan Stanley | 1,928,931 | $375.9M | 0.02% | −757,890−28.2% | Reduced |
| Northern Trust Corp | 1,696,674 | $330.6M | 0.04% | −29,019−1.7% | Reduced |
Holders of 5% or more of RMD
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Resmed Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 8.21%12.0M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| AustralianSuper Pty Ltd | 13G | 5.70%8.28M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.41%7.89M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in RMD6 members of Congress reported 17 trades in Resmed Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 5, 2026 |  Tommy Tuberville Senate · AL | Sell (full) | $1K-$15K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $1K-$15K |
| Jun 18, 2025 |  Kelly Morrison House · MN | Sell | $1K-$15K |
| Jun 18, 2025 | Kelly Morrison House · MN | Sell | $1K-$15K |
| Jun 18, 2025 | Kelly Morrison House · MN | Sell | $1K-$15K |
Senate · AL · Aug 5, 2026
Sell (full)$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K
House · MN · Jun 18, 2025
Sell$1K-$15K
House · MN · Jun 18, 2025
Sell$1K-$15K
House · MN · Jun 18, 2025
Sell$1K-$15K